PMID- 26674096
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151217
LR  - 20201001
IS  - 1758-8340 (Print)
IS  - 1758-8359 (Electronic)
IS  - 1758-8340 (Linking)
VI  - 7
IP  - 3
DP  - 2015 May
TI  - Relapse profile of early breast cancer according to immunohistochemical subtypes: 
      guidance for patient's follow up?
PG  - 144-52
LID - 10.1177/1758834015576141 [doi]
AB  - PURPOSE: To analyze the profile of annual recurrence rate (ARR) of patients with 
      early breast cancer (BC) in Tunisia. PATIENTS AND METHODS: We classified 293 
      patients with histologically confirmed early BC relapsing after 1 year of follow 
      up into three subgroups: hormone receptor (HR)+ 'HR' [estrogen receptor (ER)+ or 
      progesterone receptor (PR)+ and human epidermal growth factor receptor 2 
      (HER2)-], triple negative 'TN' (ER-, PR- and HER2 score 0/1 or fluorescence in 
      situ hybridization (FISH)/chromogenic in situ hybridization negative) and HER2 
      overexpression 'HER2' (HER2+). ARR was restricted to follow-up contribution of 
      each specified time interval. The HR group was the reference group for 
      comparison. RESULTS: A higher proportion of patients who were up to 35 years old 
      (18% versus 10%, p = 0.04), and patients with obesity (46% versus 26%, p = 0.045) 
      was seen in the TN group. Median time to relapse (MTR) was shorter in TN and HER2 
      groups than in HR patients (20 and 29 months compared with 56 months, 
      respectively, p < 0.001). In the HR group, the ARR was 22%, 16% and 10% at 3, 4 
      and 5 years respectively, becoming less than 3% at 7 years. In the TN group, 71% 
      of patients relapsed during the first 2 years and the ARR declined rapidly to 
      less than 1.5% after 4 years. In the HER2 group, the ARR peaked at 2 years (29%) 
      and decreased significantly to 7% and 3% at 5 and 7 years respectively. Adjuvant 
      trastuzumab delayed the MTR from 24 to 34 months (p = 0.022). CONCLUSION: The 
      relapse risk in Tunisian patients is higher in young women and patients with 
      HER2+ and TN tumors. A long and close follow up is recommended for patients with 
      HR and HER2. Conversely, we suggest that follow up in patients with TN could be 
      spaced after 4 years (ARR being <1.5% after this period).
FAU - Mejri, Nesrine
AU  - Mejri N
AD  - Department of Medical Oncology, Abderrahman Mami Hospital, Rue de l'Hopital, 
      2080, Ariana, Tunisia.
FAU - Boussen, H
AU  - Boussen H
AD  - Department of Medical Oncology, Abderrahman Mami Hospital, and Association of 
      Radiotherapy and Oncology of the Mediterranean (AROME), Ariana, Tunisia.
FAU - Labidi, S
AU  - Labidi S
AD  - Department of Medical Oncology, Abderrahman Mami Hospital, Ariana, Tunisia.
FAU - Benna, F
AU  - Benna F
AD  - Department of Radiation Therapy, Salah Azaiez Institute, Tunis, Tunisia.
FAU - Afrit, M
AU  - Afrit M
AD  - Department of Medical Oncology, Abderrahman Mami Hospital, Ariana, Tunisia.
FAU - Rahal, K
AU  - Rahal K
AD  - Department of Surgical Oncology, Salah Azaiez Institute, Tunis, Tunisia.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ther Adv Med Oncol
JT  - Therapeutic advances in medical oncology
JID - 101510808
PMC - PMC4406915
OTO - NOTNLM
OT  - breast cancer
OT  - hormonal receptors
OT  - human epidermal growth factor receptor 2
OT  - immunohistochemical
OT  - relapse
OT  - triple negative
COIS- Conflict of interest statement: The authors declare that there is no conflict of 
      interest.
EDAT- 2015/12/18 06:00
MHDA- 2015/12/18 06:01
PMCR- 2015/05/01
CRDT- 2015/12/18 06:00
PHST- 2015/12/18 06:00 [entrez]
PHST- 2015/12/18 06:00 [pubmed]
PHST- 2015/12/18 06:01 [medline]
PHST- 2015/05/01 00:00 [pmc-release]
AID - 10.1177_1758834015576141 [pii]
AID - 10.1177/1758834015576141 [doi]
PST - ppublish
SO  - Ther Adv Med Oncol. 2015 May;7(3):144-52. doi: 10.1177/1758834015576141.